New findings from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), confirm dihydroartemisinin-piperaquine, the first-line treatment for Plasmodium falciparum malaria infection in Cambodia, has failed in certain provinces due to parasite resistance to artemisinin and piperaquine. Dihydroartemisinin-piperaquine is an artemisinin combination therapy (ACT) for malaria that combines potent, fast-acting artemisinin with a long-acting partner drug, piperaquine. Resistance to artemisinin in parts of Southeast Asia is well-documented, but until now only a few studies have presented clear evidence of piperaquine resistance. Additional study findings suggest that artesunate, a form of artemisinin, plus mefloquine, a different long-acting partner drug, should be the first-line ACT in areas where dihydroartemisinin-piperaquine treatment has failed, the study authors note.
NIAID researchers and colleagues sought to confirm the presence of piperaquine-resistant infections in Cambodia by comparing the efficacy of dihydroartemisinin-piperaquine treatment in 204 malaria-afflicted participants aged 2 to 65 years from three provinces in Cambodia with varying levels of artemisinin resistance. After monitoring parasite levels in the blood for 63 days, investigators found parasites had reemerged despite initial clearance in 45.7 percent of participants in Pursat, 15.9 percent of participants in Preah Vihear and 1.67 percent of participants in Ratanakiri. The results indicate the ACT is failing in Pursat and Preah Vihear, where artemisinin resistance is common, but remains highly efficacious in Ratanakiri, where resistance is uncommon.
Laboratory tests showed the parasites from dihydroartemisinin-piperaquine failures contained a genetic marker of artemisinin resistance and had a decreased susceptibility to piperaquine, demonstrating that both artemisinin and piperaquine resistance contributed to treatment failures. However, the parasites also showed an increased susceptibility to mefloquine and completely lacked the molecular marker for mefloquine resistance. These findings informed new WHO guidelines reinstating artesunate plus mefloquine as the first-line ACT in Cambodia where dihydroartemisinin-piperaquine treatment has failed. The findings also provide evidence to initiate surveillance programs to track the spread of piperaquine resistance and clinical trials to test alternative combination therapies.
Amaratunga C, Lim P, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multi-site observational cohort study. The Lancet Infectious Diseases DOI: 10.1016/S1473-3099(15)00487-9 (2016).
Rick M. Fairhurst, M.D., Ph.D., chief, Malaria Pathogenesis and Human Immunity Unit in NIAID's Laboratory of Malaria and Vector Research, is available to comment on this research.
To schedule interviews, please contact Jennifer Routh, (301) 402-1663, email@example.com.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®